TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANDOVER, Mass., Feb. 24, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on February 20, 2023, TransMedics granted non-qualified stock options to purchase an aggregate of 72,774 shares of its common stock to seven employees and an aggregate of 17,092 restricted stock units to three employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants included stock options to purchase 19,732 shares of TransMedics' common stock and 12,886 restricted stock units granted to Nick Corcoran, the Company's Senior Vice President of Supply Chain and Operations. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the TransMedics Group, Inc. Inducement Plan.

Read more at prnewswire.com